Obtenga las últimas noticias sobre las acciones de CytomX Therapeutics con actualizaciones sobre las tendencias del mercado, las finanzas y el análisis de Benzinga. Manténgase informado sobre el rendimiento de CTMX

Últimas noticias sobre

CYTOMX THERAPEUTICS INC

CytomX Therapeutics

CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

CytomX Therapeutics Inc

News

Financing

Press Releases

CytomX Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock

CytomX Therapeutics Announces First Patient Dosed in Combination Arm of Phase 1 Study of CX-801 plus KEYTRUDA® (pembrolizumab) in Patients with Metastatic Melanoma

CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference

Small Cap

Opinion

Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers

CytomX Therapeutics to Report Second Quarter 2025 Financial Results on August 7, 2025

Earnings

CytomX Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update

Health Care

CytomX Therapeutics Provides Update on CX-2051 Phase 1 Study

CytomX Therapeutics to Present at Upcoming September Investor Conferences

Management

CytomX Therapeutics Appoints Rachael Lester as Chief Business Officer

CytomX Therapeutics to Report Third Quarter 2025 Financial Results on November 6, 2025

CLDI

CRSP

CTMX

IBRX

VRTX

Absci

ADC Therapeutics

Akebia Therapeutics

Bicycle Therapeutics plc - American Depositary Shares

Bicycle Therapeutics

Cullinan Therapeutics, Inc. - Common Stock

Cullinan Therapeutics

COMPASS Pathways Plc - American Depository Shares

Compass Pathways

Compass Therapeutics, Inc. - Common Stock

Compass Therapeutics

Corvus Pharmaceuticals, Inc. - Common Stock

Corvus Pharma

DBV Technologies S.A. - American Depositary Shares

DBV Technologies

4D Molecular Therapeutics, Inc. - Common Stock

4D Molecular Therapeutics

Gossamer Bio

Inventiva S.A. - American Depository Shares

Inventiva

Jade Biosciences

KalVista Pharmaceuticals, Inc. - Common Stock

KalVista Pharmaceuticals

Keros Therapeutics

Lexicon Pharmaceuticals, Inc. - Common Stock

Lexicon Pharmaceuticals

Monopar Therapeutics

NovaBridge Biosciences - American Depositary Shares

NovaBridge Biosciences

Neurogene

Ocugen

Olema Pharmaceuticals, Inc. - Common Stock

Olema Pharmaceuticals

Organogenesis Holdings

Prothena Corporation plc - Ordinary Shares

Prothena Corp

Rigel Pharmaceuticals, Inc. - Common Stock

Comments

CytomX Therapeutics Noticias bursátiles

Noticias

Últimas noticias sobre

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL